Key Highlights

● Johnson & Johnson closed at $267.61 on October 22, among the Dow's strongest gainers.

● Health care closed at a record high even as the broader market slumped.

● The company had no company-specific news.

● Trading volume reached 18.79 billion shares against a 17.19 billion average.

Johnson & Johnson (NYSE:JNJ) rallied on Thursday, October 22, 2026, closing at $267.61 and ranking among the strongest gainers on the Dow Jones Industrial Average.

The drugmaker and medical-device company had no company-specific news. Instead, it joined a defensive charge into health care, a sector that closed at a record high even as the broader market slumped.

Money ran from tech toward health care

The day belonged to the rotation. Artificial-intelligence and semiconductor stocks sold off hard after Meta Platforms (NASDAQ:META) laid out heavy capital-spending plans and reported negative free cash flow, and after Lam Research (NASDAQ:LRCX) flagged supply constraints in its outlook. The Nasdaq Composite fell 694.00 points, and the S&P 500 dropped 93.74 points to 7,663.43, its worst session since July.

Investors did not abandon stocks altogether. They moved into businesses whose earnings tend to hold up regardless of the economic or technology cycle. About two of every three S&P 500 stocks rose, according to market reports, and the equal-weight S&P 500 gained.

Health care was a prime destination. The sector hit a record despite a steep drop in Moderna (NASDAQ:MRNA), which was one of the weakest performers in the S&P 500 after data from its melanoma vaccine trial with Merck (NYSE:MRK) reportedly leaked ahead of a scheduled presentation. Johnson & Johnson's gain helped offset that drag.

Why J&J fits a nervous market

Johnson & Johnson sells prescription medicines and medical devices, products that patients and hospitals keep buying whether stock markets are calm or not. That reliability, combined with a long record of paying dividends, makes it a natural refuge when growth stocks wobble.

Falling bond yields added to the appeal. Treasuries rallied strongly, and the 10-year yield closed back below a closely watched threshold for the first time since September 22. When yields fall, the steady payouts of large defensive companies look more attractive by comparison.

Other defensive pockets moved in step. Consumer staples had their best day since April 2025 and also set a record, led by Procter & Gamble (NYSE:PG)'s strongest gain since March 2020. Utilities and financials rose as well.

The Dow held up

The Dow Jones Industrial Average, home to several of these defensive heavyweights, ended up 11.89 points at 52,867.98, essentially flat and at a one-month high, according to market data. Johnson & Johnson, Procter & Gamble, Home Depot (NYSE:HD) and Verizon (NYSE:VZ) helped offset sharp losses in Nvidia (NASDAQ:NVDA), Amazon (NASDAQ:AMZN) and Caterpillar (NYSE:CAT).

Fellow health care name Amgen (NASDAQ:AMGN) also gained, while Merck slipped as the Moderna vaccine data was treated as a sell-the-news event by some analysts.

Volume was heavy, with 18.79 billion shares traded on US exchanges, compared with an average of 17.19 billion over the prior 20 sessions, according to market data. That suggests the rotation was more than a few isolated trades.

Johnson & Johnson Looks to Moderna Data and Big Tech

The durability of the rotation is the big question. Next week brings the Federal Reserve's decision on October 28 and earnings from Microsoft (NASDAQ:MSFT) and Alphabet (NASDAQ:GOOGL) the same day, followed by Amazon on October 29. Strong tech results could pull money back toward AI names, while further disappointment could keep health care stocks like Johnson & Johnson in favor. Moderna's full melanoma data at the ESMO conference on Saturday will also be closely watched across the sector.